HUYABIO International has pioneered an innovative approach for partnering with Chinese research institutions and pharmaceutical companies. HUYABIO identifies and licenses the most promising pre-clinical and clinical stage compounds in China, leverages and extends the research efforts of its Chinese partners, and provides a bridge into the international development process and global biopharma market. Because many of the compounds have already been validated through a rigorous discovery, selection and development process in China, this model streamlines and accelerates development globally, while lowering risk. Moreover, the strength of HUYABIO’s relationships with its Chinese partners ensures a continuous source of compounds for the future.